What does bid size mean in a stock quote?
Bid size is the displayed quantity attached to a bid at its shown price. The screen or feed specification determines whether size is represented as shares or lots.
RESEARCH LIBRARY
Bid size is the displayed quantity attached to a bid at its shown price. The screen or feed specification determines whether size is represented as shares or lots.
The official close follows the listing exchange’s closing-price method. A last-sale field can update with a later eligible trade or refer to a different session, depending on the data vendor.
Extended-hours platforms can display different venues or data coverage. Compare the timestamp, session and route before deciding whether the quotes describe the same accessible market.
The clearest downside for Datadog is the way usage-based cloud observability and customer expansion can translate into weaker cash per share. Customer efforts to cut cloud bills can also reduce the number of monitored workloads. Large cloud vendors or open-source tools can put pressure on pricing. I would watch for that operating change and a deterioration in the financial measures below before reconsidering the stock’s risk.
I would wait for a price supported by the cash and earnings Datadog can sustain. The valuation hinges on usage-based cloud observability and customer expansion. The dated filing inputs set a starting point. A current price verdict requires a matching market quotation and a justified normalized base.
Datadog generated positive operating cash after the selected capital purchases, but equity compensation is large relative to that cash figure. I would track cash generation per diluted share and the cost of offsetting dilution before treating the accounting cash result as strong owner economics.
Constructive if direct-to-consumer returns complement parks. Parks, sports and entertainment monetize audiences in different ways. Streaming can improve the mix only if pricing, retention and content costs produce durable operating cash.
Selective with patent and research risks priced in. Legacy franchises can fund a transition, but replacement sales must arrive before major exclusivity losses. Business-development spending should be assessed against cash returns rather than deal volume.
Pfizer’s post-COVID business is improving enough to support a selective value buy, but the turnaround remains incomplete. Non-COVID products grew 7% operationally in the latest quarter, while total revenue was roughly flat. At about 10 times guided adjusted earnings, the price leaves room for modest progress; the investment should depend on profitable portfolio renewal rather than a return to pandemic revenue.
Pfizer is a selective value buy at the November 3 close of $30, suitable for investors willing to accept a slow pharmaceutical turnaround. About 10 times guided adjusted earnings provides more valuation room than many large drug companies. Non-COVID products are growing, but the company still needs pipeline and acquisition returns to replace mature revenue. I would buy modestly rather than treat the low multiple as proof that the problems are solved.
Pfizer raised guidance while non-COVID and recently launched products grew. A low guided multiple supports selective value buying, with portfolio and cash risks still relevant.
Disney’s Entertainment SVOD operation is meaningfully profitable on its disclosed non-GAAP measure: Q3 operating income was $712 million on $5.532 billion of revenue, a 12.9% margin. That improves my investment view and supports a selective purchase. I would still normalize for spending timing and keep Sports, live TV and the rest of Disney separate.